H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 14.3% of adults in Rochester have diagnosed diabetes — 2.3 points above the U.S. 12% figure. Census population 211,328. New York Medicare wound biologics: National Government Services (NGS) (JK). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Rochester clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Rochester storefront.
Orthobiologic Treatments for Your Practice in Rochester, NY for clinics & physicians. Premium orthobiologi… Compliance support & pricing — contact Hawk Medical.
Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 14.3% of adults in Rochester have diagnosed diabetes — 2.3 points above the U.S. 12% figure. 10.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick orthobiologic treatments against that mix.
National Orthobiologic Treatments for Your Practice notes (how the product actually works)JK reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Rochester is 14.3% or not. PLACES is planning data. The LCD is the claim.
We are not going to invent a Rochester warehouse or a five-star local review. What you get is orthobiologic treatments from FDA-registered sources, lot paperwork, and someone who has run the same SOPs in clinic — Joe Bradley. The local numbers on this page are CDC PLACES and CMS JK, not marketing adjectives.
CDC PLACES (2023, crude prevalence) estimates 14.3% of adults — 2.3 points above the U.S. 12% figure. Obesity is 38%; arthritis is 24.9%. That is place-level BRFSS modeling, not a clinic census and not a Rochester trial.
No. National Government Services (NGS) writes coverage. We train staff on documentation patterns those articles already require (wound measurements, conservative care, units). That is support, not a coverage guarantee.
No. Hawk Medical does not distribute products as “stem cell therapy.” HCT/P 361 allografts are regulated under 21 CFR 1271 for homologous use and minimal manipulation. PRP is autologous. Marketing that blurs those lanes is a compliance problem in every state, including New York.
Yes. Tissue products come from FDA-registered banks with donor screening and lot traceability. Your receiving SOP should file IFU, lot, and indication with the chart. That packet is what JK reviewers and surveyors expect — not a brochure.
If you operate in New York and another MAC state, say it on the first call. JK will not port 1:1. We would rather split utilization than watch a sister clinic copy Rochester tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Rochester, NY.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Rochester is JK geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Rochester — 2.3 points above the U.S. 12% figure. Planning input, not an outcomes claim.
New York Part B wound biologics follow this contractor (siblings: CT, MA, ME, NH, RI, VT). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Rochester. Useful for joint-program math; still needs a diagnosis and privileging.
No Rochester storefront. Joe Bradley is an active practice owner. orthobiologic treatments stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.